Latest Licensing News

Weebit Nano has lifted its FY 2026 revenue forecast by over 12%, citing growth in customer projects ahead of its full-year results.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for its suite of 27 ETFs on the ASX, updating investment strategies, fee structures, risk factors, and operational details.

Minbos Resources has secured A$4 million in a discounted placement to fund key milestones at its Cabinda Phosphate Project, including mining commencement and plant construction progress.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

Hazer Group has completed a key commercial-scale hydrogen process design package with KBR, boosting its readiness for large-scale deployment and expanding its project pipeline across multiple sectors and geographies.

Firebird Metals has achieved a key milestone under the ARENA Battery Breakthrough Initiative, unlocking a A$1 million non-dilutive payment and progressing site development for its Australian Demonstration Plant in Perth.

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.

Marquee Resources has initiated a non-renounceable rights issue priced at $0.005 per share, aiming to raise just over $1 million. Eligible shareholders will receive free attaching options, with the offer closing on 27 July 2026.

Meteoric Resources has expanded its Ore Reserve at the Caldeira Rare Earth Project in Brazil by 42%, underpinning over 20 years of production and reinforcing its Tier 1 status in the global rare earths market.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Brazilian Rare Earths (ASX: BRE) reports standout drill results with 1.3m at 10.9% TREO including 5.8% Y2O3, expanding its Monte Alto District rare earth footprint in Bahia, Brazil.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.